Strategies to tackle SARS-CoV-2 Mu, a newly classified variant of interest likely to resist currently available COVID-19 vaccines현재 사용 가능한 COVID-19 백신에 저항할 가능성이 있는 새로 분류된 관심 변종인 SARS-CoV-2 Mu에 대처하기 위한 전략Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), MERS, SARS, 변종, 유전자 메커니즘, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration adopted approach B.1 lineage B.1.621 BNT161b2 booster dose Characteristics coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccine COVID-19 vaccine development Evidence exacerbated Genetic genomic Genomic surveillance global mass vaccination Health implementation infections Intervention Lineage mass vaccination Mu variant mutations Neutralizing non-pharmaceutical interventions (NPIs) NPIs potential risk public health measure public health measures Recombination reported required respiratory restrict SARS-CoV-2 SARS-CoV-2 B.1.621 SARS-CoV-2 virus sera shown Strains Strategy sub-lineage B.1.621.1 Surveillance survivor the SARS-CoV-2 virus therapeutic threat vaccination Vaccine vaccine breakthrough. Vaccine development variant variants [DOI] 10.1080/21645515.2022.2027197 PMC 바로가기 [Article Type] Article
Binding and neutralizing abilities of antibodies towards SARS-CoV-2 S2 domainSARS-CoV-2 S2 도메인에 대한 항체의 결합 및 중화 능력Article Published on 2022-11-302022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antibodies antibody B.1.1.7 B.1.351 B.1.617.2 B.1.621 binding binding activity carried conserved convalescent patient coronavirus coronavirus 2 coronavirus disease Coronavirus disease 2019 COVID-19 determined by domain ELISA enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay evaluated Evidence Immune escape immune protection mAb mAbs MERS MERS-CoV Middle East Middle East respiratory syndrome Middle East respiratory syndrome Coronavirus molecular monoclonal antibodies monoclonal antibody N Terminal N terminal domain NAbs Neutralization assay neutralization assay. Neutralizing Neutralizing activity Neutralizing antibodies neutralizing antibody NTD P.1 Protein pseudo-virus RBD Receptor binding domain reported Research respiratory Result S protein S proteins S2 protein S2 subunit SARS-CoV SARS-CoV-2 SARS-CoV-2 RBD SARS-CoV-2 S SARS-CoV-2 S2 SARS-CoV-2 WT Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus significantly specific antibodies subunit target targets terminal Vaccine design variant variants wild-type [DOI] 10.1080/21645515.2022.2055373 PMC 바로가기 [Article Type] Article
Most frequently harboured missense variants of hACE2 across different populations exhibit varying patterns of binding interaction with spike glycoproteins of emerging SARS-CoV-2 of different lineagesArticle Published on 2022-09-012022-11-16 Journal: Computers in biology and medicine [Category] COVID19(2023년), SARS, 변종, [키워드] accumulated African amino acid substitution analysis AY.1 B.1.617.2 B.1.621 binding binding interaction China Combination Complexes COVID-19 Delta docking domain Effect exhibited Factors Genetic hACE2 hACE2. Host human Angiotensin-converting enzyme Interaction investigated Latin Lineage missense variant Missense variants MM/GBSA molecular docking molecular docking analysis molecular dynamics Molecular dynamics simulation MOST Mutation mutations non-Finnish European omicron Population populations predict prevalent protein stability rate of infection RBD Receptor binding risk SARS-CoV-2 SARS-CoV-2 RBD South Asian spike glycoprotein suffered the SARS-CoV-2 Transmissibility variant variants variants of concern viral variant virus was performed Wuhan [DOI] 10.1016/j.compbiomed.2022.105903 PMC 바로가기
Characterization of the SARS-CoV-2 B.1.621 (Mu) variantSARS-CoV-2 B.1.621(Mu) 변종 특성화Article Published on 2022-08-102022-09-11 Journal: Science Translational Medicine [Category] SARS, 변종, 진단, [키워드] Antibody neutralization Antibody titer Antibody titers B.1.351 B.1.351, Beta B.1.621 Beta Beta variant characterization convalescent serum hamster hamsters Health Organization immune response individual Infection Live virus Moderna mRNA vaccines neutralization Neutralization assay neutralized Neutralizing antibody titer Pfizer/BioNTech reduced reduction SARS-CoV-2 second vaccination sensitivity serum serum sample serum samples subsequent the SARS-CoV-2 variant World Health Organization [DOI] 10.1126/scitranslmed.abm4908 PMC 바로가기 [Article Type] Article
A pyrosequencing protocol for rapid identification of SARS-CoV-2 variantsSARS-CoV-2 변이체의 신속한 식별을 위한 파이로시퀀싱 프로토콜Article Published on 2022-08-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, 치료제, [키워드] (Alpha) (Beta) acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Alpha B.1.1 B.1.1.529 B.1.1.7 B.1.351 B.1.525 B.1.617.1 B.1.617.2 B.1.621 Beta circulating circulating variant circulating variants confidence Coronaviridae coronavirus costly Delta differentiation distribution effort Epsilon Eta Gamma geographical regions information Iota lineages MONITOR monoclonal antibody monoclonal antibody therapies monoclonal antibody treatment Mutation Next-generation sequencing NGS omicron Patient protocol pyrosequencing reported respiratory reverse transcription SARS-CoV-2 SARS-CoV-2 surveillance SARS-CoV-2 variant Sequencing Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus Spike protein Surveillance the United State therapy time-consuming United States variant Variant. variants [DOI] 10.1002/jmv.27770 PMC 바로가기 [Article Type] Article
Impact of SARS-CoV-2 Mu variant on vaccine effectiveness: A comparative genomics study at the peak of the third wave in Bogota, ColombiaSARS-CoV-2 Mu 변이체가 백신 효과에 미치는 영향: 콜롬비아 보고타에서 3차 유행이 정점에 달했을 때의 비교 유전체학 연구Article Published on 2022-08-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), MERS, SARS, 변종, 유전자 메커니즘, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 assist B.1.621 Breakthrough infection circulation Coronavirus-2 effort epidemiological epidemiological surveillance evaluate genomic genomics study highlight Immune escape Impact infecting Lineage Mutation omicron respiratory RT-PCR SARS-CoV-2 Sequencing Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus specific mutation specific mutations subjects Surveillance vaccinated individual vaccinated individuals vaccination Vaccine variant variants variants. [DOI] 10.1002/jmv.27808 PMC 바로가기 [Article Type] Article
Active surveillance and early detection of community transmission of SARS-CoV-2 Mu variant (B.1.621) in the Brazilian Amazon브라질 아마존에서 SARS-CoV-2 Mu 변종(B.1.621) 지역사회 전파에 대한 능동적 감시 및 조기 탐지Article Published on 2022-07-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] Active surveillance All participants Amino acid amino acid substitution Antigen assist Asymptomatic B.1.621 blood sample Blood samples Brazilian Amazon Chain Reaction circulating city collected Community community transmission Contact tracing country COVID-19 patient Diagnosis diagnostic test ELISA testing Emergency epidemiological data followed by genomic genomic sequencing Genomic surveillance highlight household contacts identify IgA IgG IgG levels IgM antibody IgM antibody levels individual infected individual information mild symptoms Mu variant nasopharyngeal swabs one patient ORF1a ORF7a outpatients Participants polymerase chain reaction Porto prospective cohort Rapid diagnostic test reference sequence Reverse transcription-polymerase chain reaction RT-PCR SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants SARS-CoV-2. sequenced specimen Surveillance Swab tested Travel variant virus virus viruses [DOI] 10.1002/jmv.27686 PMC 바로가기 [Article Type] Article
Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trialSARS-CoV-2 및 S-Trimer(SCB-2019) COVID-19 백신에 대한 이전 노출이 재감염 위험에 미치는 영향: 무작위 배정, 이중 맹검, 위약 대조, 2상 및 3상 시험Clinical Trial Published on 2022-07-012022-09-11 Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), SARS, 변종, 임상, [키워드] 1:1 95% CI addition Alpha assigned attack rates B.1.1.7 B.1.351 B.1.617.2 B.1.621 baseline Beta calculate CEPI Clover Coalition confirmed case COVID-19 COVID-19 infection COVID-19 vaccination COVID-19 vaccine dose double-blind double-blinded Efficacy enrolled Evidence evidence of exposure to FIVE groups hospitalisation Impact injection site pain Innovation IQVIA Lambda Local lowest moderate-to-severe COVID-19 multicentre no evidence of P.1 participant Participants Phase 2 Placebo placebo-controlled placebo-controlled trial Primary outcome Primary outcomes protection Protective randomised Randomly Rate reactogenicity Real-time PCR receive recipients recombinant Reinfection reported response risk SARS-CoV-2 SARS-CoV-2-naïve participants SCB-2019 Secondary analyses secondary analysis Serious Adverse Event Serious Adverse Events severe adverse events severe COVID-19 severity subsequent subset symptomatic systemic adverse event systemic adverse events technology Trial USA vaccination Vaccine vaccine dose vaccine efficacy variant variants Viral variants with COVID-19 [DOI] 10.1016/S1473-3099(22)00144-X PMC 바로가기 [Article Type] Clinical Trial
SARS-CoV-2: phenotype, genotype, and characterization of different variantsSARS-CoV-2: 다양한 변이체의 표현형, 유전자형 및 특성화Article Published on 2022-06-172022-09-11 Journal: Cellular & Molecular Biology Letters [Category] COVID19(2023년), SARS, 변종, 치료법, [키워드] ACE2 acute respiratory syndrome acute respiratory syndrome coronavirus Alpha Amino acid amino acid sequence angiotensin Angiotensin-converting enzyme angiotensin-converting enzyme 2 Antibiotics antiviral drugs B.1.1.529 B.1.1.7 B.1.351 B.1.617.2 B.1.621 Beta can not Clusters coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 Delta domain eliminated envelope epidemiological data exceptional family Coronaviridae Gamma Genetic variation Genome Genotype Glucocorticoids Health Organization help host cells IFN-α2b Immunoglobulin include infect Infection international public health Intravenous immunoglobulin Lambda membrane Nidovirales nucleocapsid omicron P.1 patients phenotype plasma plasma therapy positive Prevent Protein receptor risk of infection RNA RNA virus SARS-CoV-2 SARS-CoV-2 variants Seven severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 Spread structural protein structural proteins subtype the Coronaviridae therapy Transmission treat vaccination vaccine. variant Variation variations VoC WHO World Health Organization [DOI] 10.1186/s11658-022-00352-6 PMC 바로가기 [Article Type] Article
The SARS-CoV-2 Mu variant should not be left aside: It warrants attention for its immuno-escaping abilitySARS-CoV-2 Mu 변종은 방치해서는 안 됩니다. 면역 탈출 능력에 대한 주의가 필요합니다.Article Published on 2022-06-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, [키워드] antibodies antigenic antigenic variation appear B.1.621 bioinformatics biostatistics biostatistics & constellation COVID-19 pandemic Delta delta variant examined genetics immune resistance inactivated Inactivated vaccine less Lineage Mutation predicted SARS Coronavirus SARS-CoV-2 SARS-CoV-2 variants Spike protein variant virus virus classification virus classification. [DOI] 10.1002/jmv.27663 PMC 바로가기 [Article Type] Article